普芦卡必利联合乳果糖在顽固性便秘中的应用研究

doi:10.3877/cma.j.issn.2095-3224.2017.03.007

中华结直肠疾病电子杂志 ›› 2017, Vol. 06 ›› Issue (03) : 207 -211. doi: 10.3877/cma.j.issn.2095-3224.2017.03.007

所属专题：文献；

论著

普芦卡必利联合乳果糖在顽固性便秘中的应用研究

汤东¹, 王杰¹, 黄玉琴¹, 周怀成¹, 史友权¹, 田滢², 陆永蝶², 邹胜男², 陈宇吉², 孙晓明², 徐梦月², 孙鹏翔², 王道荣¹^,^†(

), 李宁³

^1. 225001　扬州大学临床医学院（江苏省苏北人民医院）普外科、普通外科研究所
^2. 225001　扬州大学医学院临床医学系
^3. 210002　南京大学医学院临床学院（南京军区南京总医院全军普通外科研究所）普通外科研究所

收稿日期:2017-03-19 出版日期:2017-06-25
通信作者: 王道荣

Application of the combination of prucalopride and lactulose in the refractory constipation

Dong Tang¹, Jie Wang¹, Yuqin Huang¹, Huaicheng Zhou¹, Youquan Shi¹, Ying Tian², Yongdie Lu², Shengnan Zou², Yuji Chen², Xiaoming Sun², Mengyue Xu², Pengxiang Sun², Daorong Wang¹^,^†(), Ning Li³

^1. Department of General Surgery, Institute of General Surgery, Clinical Medical College, Yangzhou University (Subei People′s Hospital of Jiangsu Province), Yangzhou 225001, China
^2. Clinical Medicine, Medical College of Yangzhou University, Yangzhou 225001, China
^3. Research Institute of General Surgery, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China

Received:2017-03-19 Published:2017-06-25
Corresponding author: Daorong Wang
About author:
Corresponding author: Wang Daorong, Email: daorong666@sina.com

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

汤东, 王杰, 黄玉琴, 周怀成, 史友权, 田滢, 陆永蝶, 邹胜男, 陈宇吉, 孙晓明, 徐梦月, 孙鹏翔, 王道荣, 李宁. 普芦卡必利联合乳果糖在顽固性便秘中的应用研究[J/OL]. 中华结直肠疾病电子杂志, 2017, 06(03): 207-211.

Dong Tang, Jie Wang, Yuqin Huang, Huaicheng Zhou, Youquan Shi, Ying Tian, Yongdie Lu, Shengnan Zou, Yuji Chen, Xiaoming Sun, Mengyue Xu, Pengxiang Sun, Daorong Wang, Ning Li. Application of the combination of prucalopride and lactulose in the refractory constipation[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(03): 207-211.

目的

评价普芦卡必利联合乳果糖对顽固性便秘患者的疗效。

方法

2013年1月至2015年6月，对35例使用普芦卡必利（2 mg/天）单药连续4周治疗效果欠佳即平均每周完全自发排便（CSBMs）≤2次的顽固性便秘患者采用普芦卡必利（2 mg/天）联合乳果糖（15 ml×2次/天）连续8周方案进行治疗。观察指标为：服药后首次完全自发排便所需时间和每周平均CSBMs次数，并采用Bristol粪便评分量表、胃肠生活质量评分（GIQLI）、Wexner便秘评分和健康状况调查问卷（SF-36）比较联合治疗前后患者便秘症状和生活质量改善情况，并观察不良反应事件。

结果

患者联合治疗前后首次CSBMs所需时间为（6.7±3.2）天和（2.4±2.1）天（t=10.161，P<0.01）；平均每周CSBMs为（0.86±0.77）次/周（单药治疗前4周）和（5.26±6.09）次/周（联合治疗后8周）（t=-4.363，P<0.01）；患者总体便秘症状和生活质量各评分较联合治疗前明显改善（均P<0.01）。联合治疗8周后35例患者中有25例每周平均CSBMs≥3次，有效率达71.4%（25/35）。治疗期间不良反应为轻中度恶心、头痛、腹泻和腹胀，持续数天后即缓解。

结论

普芦卡必利联合乳果糖能进一步改善顽固性便秘患者的便秘症状和生活质量，值得临床推广应用。

关键词: 便秘, 治疗, 普芦卡必利, 乳果糖, 联合用药, 效果

Objective

To evaluation of the efficacy of the combination of prucalopride and lactulose in the patients with refractory constipation.

Methods

From January 2013 to June 2015, thirty-five cases of patients with refractory constipation whom were not benefited from single drug treatment (prucalopride, 2 mg/day, for 4 weeks, and the average weekly complete spontaneous bowel movements<3 times) were treated by the combination of prucalopride (2 mg/day) and lactulose (15 ml×2 times/day) for 8 weeks. The time and number of complete spontaneous bowel movements (CSBMs) was observed. The bristol stool scale, gastrointestinal quality of life score (GIQLI), Wexner constipation score and a 36-item short-form (SF-36) were compared before and after combined treatment of prucalopride and lactulose in patients with refractory constipation to observe the improvement of constipation and quality of life, and the adverse reaction events.

Results

The first time of CSBM is (6.7±3.2) d and (2.4±2.1) d h (t=10.161, P<0.01) in the study group before and after combined medication. The average number of CSBMs is (0.86±0.77) times/week (4 weeks before combined medication) and (5.26±6.09) times/week (8 weeks after combined medication), respectively (t=-4.363, P<0.01). Compared to the single drug medication, the constipation symptoms and quality of life of the patients were significantly improved after combined medication (all P<0.01). 25 cases in 35 patients with refractory constipation has CSBMs more than 3 times a week after 8 weeks of combination of prucalopride and lactulose, with the effective rate 71.4% (25/35). Only little mild and moderate adverse reactions such as nausea, headache and abdominal distension were observed and were natural disappeared several days after medication.

Conclusion

The combination of prucalopride and lactulose can be effectively improved the related symptoms and quality of life of the patients with refractory constipation, which is worthy of clinical application.

Key words: Constipation, Therapy, Prucalopride, Lactulose, Combined combination, Effect

表1 35例顽固性便秘患者联合治疗前后GIQLI、Wexner便秘评分和CSBMs比较结果（±s）

评估时间	胃肠生活质量评分（分）	Wexner便秘评分（分）	完全自发排便CSBM（次/周）
单药治疗前4周	94.66±15.68	22.94±3.36	0.86±0.37
联合治疗后8周	66.71±23.43	14.26±6.8	5.26±2.09
t值	7.166	7.843	-4.363
P值	<0.001	<0.001	<0.001

表1 35例顽固性便秘患者联合治疗前后GIQLI、Wexner便秘评分和CSBMs比较结果（±s）

评估时间	胃肠生活质量评分（分）	Wexner便秘评分（分）	完全自发排便CSBM（次/周）
单药治疗前4周	94.66±15.68	22.94±3.36	0.86±0.37
联合治疗后8周	66.71±23.43	14.26±6.8	5.26±2.09
t值	7.166	7.843	-4.363
P值	<0.001	<0.001	<0.001

表2 35例顽固性便秘患者联合治疗前后Bristol粪便评分结果（例）

评估时间	Bristol粪便评分
评估时间	第1~3型	第4~6型	第7型
单药治疗前4周	23	12	0
联合治疗后8周	7	22	6
Χ²值	17.475
P值	<0.001

表2 35例顽固性便秘患者联合治疗前后Bristol粪便评分结果（例）

评估时间	Bristol粪便评分
评估时间	第1~3型	第4~6型	第7型
单药治疗前4周	23	12	0
联合治疗后8周	7	22	6
Χ²值	17.475
P值	<0.001

表3 35例顽固性便秘患者联合治疗前后SF-36各因子得分比较（分，±s）

评估时间	生理功能	生理职能	躯体疼痛	总体健康	活力	社会功能	情感职能	精神健康
单药治疗前4周	25.11±2.46	5.97±1.27	6.78±2.82	17.56±3.75	17.54±3.68	5.89±1.83	4.83±0.89	19.20±5.26
联合治疗后8周	25.95±2.79	6.63±1.35	7.72±2.87	18.68±3.96	18.34±3.79	6.66±2.04	5.06±0.87	20.26±5.58
t值	-4.833	-5.36	-5.303	-4.721	-2.758	-4.552	-4.179	-4.793
P值	<0.001	<0.001	<0.001	<0.001	0.009	<0.001	<0.001	<0.001

表3 35例顽固性便秘患者联合治疗前后SF-36各因子得分比较（分，±s）

评估时间	生理功能	生理职能	躯体疼痛	总体健康	活力	社会功能	情感职能	精神健康
单药治疗前4周	25.11±2.46	5.97±1.27	6.78±2.82	17.56±3.75	17.54±3.68	5.89±1.83	4.83±0.89	19.20±5.26
联合治疗后8周	25.95±2.79	6.63±1.35	7.72±2.87	18.68±3.96	18.34±3.79	6.66±2.04	5.06±0.87	20.26±5.58
t值	-4.833	-5.36	-5.303	-4.721	-2.758	-4.552	-4.179	-4.793
P值	<0.001	<0.001	<0.001	<0.001	0.009	<0.001	<0.001	<0.001

[1]	Shah BJ, Rughwani N, Rose S. In the clinic. Constipation [J]. Ann Intern Med, 2015, 162(7): Itc1.
[2]	Wald A. Constipation: pathophysiology and management [J]. Curr Opin Gastroenterol, 2015, 31(1): 45-49.
[3]	Feng X, Su Y, Jiang J, et al. Changes in fecal and colonic mucosal microbiota of patients with refractory constipation after a subtotal colectomy [J]. Am Surg, 2015, 81(2): 198-206.
[4]	Kuscher S, Kronberger I, Oberwalder M, et al. Rare morphological disorder in therapy refractory chronic constipation [J]. Int J Colorectal Dis, 2015, 30(4): 579-580.
[5]	Bassotti G, Blandizzi C. Understanding and treating refractory constipation [J]. World J Gastrointest Pharmacol Ther, 2014, 5(2): 77-85.
[6]	Wald A. Constipation: Advances in Diagnosis and Treatment [J]. Jama, 2016, 315(2): 185-191.
[7]	Bellacosa L, Cogliandro R, Cremon C, et al. Some practical questions on chronic stipsis treatment with prucalopride [J]. Minerva Gastroenterol Dietol, 2014, 60(1): 85-99.
[8]	Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation [J]. Am J Gastroenterol, 2015, 110(5): 741-748.
[9]	Xin HW, Fang XC, Zhu LM, et al. Diagnosis of functional constipation: agreement between Rome III and Rome II criteria and evaluation for the practicality [J]. J Dig Dis, 2014, 15(6): 314-320.
[10]	Camilleri M. Inclusion criteria for pharmacodynamic and clinical trials in chronic idiopathic constipation: pitfalls in using Rome III for functional constipation [J]. Therap Adv Gastroenterol, 2011, 4(3): 159-163.
[11]	Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument [J]. Br J Surg, 1995, 82(2): 216-222.
[12]	Agachan F, Chen T, Pfeifer J, et al. A constipation scoring system to simplify evaluation and management of constipated patients [J]. Dis Colon Rectum, 1996, 39(6): 681-685.
[13]	Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection [J]. Med Care, 1992, 30(6): 473-483.
[14]	Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time [J]. Scand J Gastroenterol, 1997, 32(9): 920-924.
[15]	Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation [J]. Can J Gastroenterol, 2011, 25 Suppl B: 11b-15b.
[16]	Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis [J]. Am J Gastroenterol, 2011, 106(9): 1582-1591; quiz 1581, 1592.
[17]	Irvine EJ, Ferrazzi S, Pare P, et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization [J]. Am J Gastroenterol, 2002, 97(8): 1986-1993.
[18]	Pfeifer J. Surgical options to treat constipation: A brief overview [J]. Rozhl Chir, 2015, 94(9): 349-361.
[19]	Bassotti G, Villanacci V. Can "functional" constipation be considered as a form of enteric neuro-gliopathy? [J]Glia, 2011, 59(3): 345-350.
[20]	Wiskur B, Greenwood-Van Meerveld B. The aging colon: the role of enteric neurodegeneration in constipation [J]. Curr Gastroenterol Rep, 2010, 12(6): 507-512.
[21]	Knowles CH, Farrugia G. Gastrointestinal neuromuscular pathology in chronic constipation [J]. Best Pract Res Clin Gastroenterol, 2011, 25(1): 43-57.
[22]	Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation [J]. Aliment Pharmacol Ther, 2014, 39(3): 239-253.
[23]	Tack J, Stanghellini V, Dubois D, et al. Effect of prucalopride on symptoms of chronic constipation [J]. Neurogastroenterol Motil, 2014, 26(1): 21-27.
[24]	Piessevaux H, Corazziari E, Rey E, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride [J]. Neurogastroenterol Motil, 2015, 27(6): 805-815.
[25]	Garnock-Jones KP. Prucalopride: A Review in Chronic Idiopathic Constipation [J]. Drugs, 2016, 76(1): 99-110.
[26]	Coffin B, Causse C. Constipation assessment scales in adults: a literature review including the new Bowel Function Index [J]. Expert Rev Gastroenterol Hepatol, 2011, 5(5): 601-613.
[27]	Aydin S. Lactulose in fat-free milk, rather than increased ghrelin and motilin level, might help for solving constipation: author update [J]. Nutrition, 2011, 27(6): 731.
[28]	Wang Z, Qian JX, Jiao XD, et al. Clinical observation of prophylactic lactulose for prevention of oral morphine-induced constipation [J]. Zhonghua Yi Xue Za Zhi, 2012, 92(42): 2968-2971.
[29]	Ruston T, Hunter K, Cummings G, et al. Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systematic review [J]. Can Oncol Nurs J, 2013, 23(4): 236-246.
[30]	Wang YF. Curative effect of mosapride vs prucalopride in treatment of chronic constipation in elderly patients [J]. World Chinese Journal of Digestology, 2015, 23(36): 5889.
[31]	Keating GM. Prucalopride: a review of its use in the management of chronic constipation [J]. Drugs, 2013, 73(17): 1935-1950.

[1]	史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(08): 778-784.
[2]	张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[3]	朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[4]	曹琮沅, 黄烁金, 何倩婷, 王安训. 平阳霉素复合剂治疗口腔颌面部脉管畸形的有效性和安全性[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 368-374.
[5]	李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[6]	陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[7]	梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[8]	刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[9]	刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[10]	袁园园, 岳乐淇, 张华兴, 武艳, 李全海. 间充质干细胞在呼吸系统疾病模型中肺组织分布及治疗机制的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 374-381.
[11]	王秋生. 胆道良性疾病诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[12]	国文凯, 纪鹏程, 毕靖茹, 谢院生. IgA 肾病的十种治疗措施[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 327-333.
[13]	帖璇, 苏晓乐, 王利华. 抗中性粒细胞胞质抗体相关性血管炎治疗研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 345-351.
[14]	崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15]	王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Application of the combination of prucalopride and lactulose in the refractory constipation

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Application of the combination of prucalopride and lactulose in the refractory constipation